Tagged with

Array In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at the time—Hospira’s strategy in Taiwan was a bit different than it was elsewhere in the world. You also said that…

PM Group Mr. Murphy, you first joined PM Group 24 years ago. How has the company, and the market, changed? My background, prior to joining PM Group, was in the pharmaceutical industry—I worked for four years for a contract manufacturer in Ireland. That manufacturer’s story is an interesting reflection of where the…

Asia-Pacific Many of your counterparts have spoken about the unique operational and strategic challenges China poses to their organizations. How does PAREXEL adapt itself to compete in China, and how does it work differently here than elsewhere in the world? First off, we know that within another two to three years…

TVGH Mr. Fang-Yue Lin was a Department of Health Minister before becoming Superintendent of TVGH just 7 short months ago. He shares with us his Insight to the reform of the 2nd generation of National Health Insurance (NHI) and vision on the emergence of New Drug Research (NDR) biotech. sector for…

regulator After the big milestone last year— the Danish Medicines Agency merging with the Danish National Board of Health— can you please comment on why this decision was taken and what synergies have since emerged? Part of this decision was due to economic reasons; we reviewed the institutions that we have…

Array Ulf Wiinberg has been CEO of Lundbeck since June 2008. He was previously with Wyeth for 27 years. Ulf Wiinberg is a board member of EFPIA in Europe and of PhRMA in the United States and serves on the Industrial Policy Committee under the Confederation of Danish Industry (Dansk Industris…

ProMetic Life Sciences Inc. Mr. Pierre Laurin is a senior executive with 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic’s platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As Chairman until March, 2011 and President and CEO of the Corporation since…

Nordic Drugs Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary of Ferring in January 1995. Several years later, in 1998, we were divested out from Ferring. Today we are owned…

ADHD You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire as a whole has grown dramatically in the past twelve years, going from approximately 400 to more than 5,000 employees…

ADHD You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire as a whole has grown dramatically in the past twelve years, going from approximately 400 to more than 5,000 employees…

ADHD You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire as a whole has grown dramatically in the past twelve years, going from approximately 400 to more than 5,000 employees…

Clinical trials The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative molecule PI-88. He also offers his perspective on the increasing synergies between Taiwan and China in the biotech sector. During our…